Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/14/2025

Glycemic Control in Diabetes Management

Monitoring Frequency

  • For patients with stable glycemic control who are meeting treatment goals, the American Diabetes Association recommends measuring HbA1c at least twice yearly, while patients whose therapy has recently changed or who are not meeting glycemic goals should be tested quarterly 1, 2, 3
  • The American Diabetes Association suggests that patients with well-controlled diabetes and stable therapy may be adequately monitored with a frequency of at least twice per year, with more frequent monitoring (every 3 months) for individuals with unstable glycemic control or therapy change, and every 6 months for those with stable glycemic control 4, 5, 6, 1, 7, 8, 9

Interpretation of HbA1c Results

  • The American Diabetes Association advises caution when interpreting A1C results in conditions affecting red blood cell turnover, such as hemolytic anemia, aplastic anemia, recent blood transfusions, hemoglobinopathies, end-stage kidney disease, pregnancy, and use of drugs that stimulate erythropoiesis 1, 2, 6, 5, 10, 1, 8, 2
  • In such cases, glucose criteria should be used exclusively for diagnosis, and alternative monitoring approaches, such as self-monitoring of blood glucose (SMBG), continuous glucose monitoring (CGM), or fructosamine or glycated albumin testing, should be considered 6, 11, 5, 10, 1, 8, 2

Target HbA1c Levels

  • The American Diabetes Association recommends an HbA1c target of <7% for most non-pregnant adults, with more stringent goals (such as <6.5%) potentially appropriate for selected individuals if achievable without significant hypoglycemia, and higher targets for children, adolescents, and individuals with limited life expectancy, extensive comorbidities, history of severe hypoglycemia, or advanced complications 2, 3, 12

Screening and Diagnosis

  • For asymptomatic adults, testing is recommended if overweight/obese (BMI ≥25 kg/m²) with one or more additional risk factors, such as age ≥40 years, history of prediabetes, or first-degree relatives with type 2 diabetes, and testing should begin at age 45 for those without risk factors, and if tests are normal, repeat at least every 3 years 3, 12
  • Additional risk factors for testing include overweight (BMI ≥24 kg/m²) or obesity (BMI ≥28 kg/m²), history of gestational diabetes, hypertension, dyslipidemia, or atherosclerotic cardiovascular disease 12

Monitoring Approaches

  • The following monitoring frequencies are recommended:
Patient Group Monitoring Frequency
Stable glycemic control Every 6 months [4, 5, 6]
Unstable glycemic control or therapy change Every 3 months [4, 5, 10, 1, 7, 8, 9]
Special populations (pregnant women, intensive insulin regimens, history of glycemic variability) More frequent monitoring [10, 1, 7, 8, 9]
Conditions affecting A1C accuracy (hemolytic anemia, blood loss, recent transfusions, etc.) Alternative monitoring approaches [5, 10, 1, 8, 2]
  • SMBG 1-2 times per day is appropriate for most prediabetic patients on metformin, as recommended by the American Diabetes Association, with the frequency of SMBG adjustable based on individual patient needs 13, 14
  • Proper technique for SMBG should be taught and periodically reassessed, as accuracy is both device and user dependent 13, 15

Complications and Treatment

  • Higher HbA1c levels (>8%) are strongly associated with increased risk of microvascular and macrovascular complications, emphasizing the importance of regular monitoring 16
  • Metformin can reduce diabetes conversion rates, with numbers needed to treat between 7-14 over a 3-year period, highlighting the importance of appropriate monitoring 17

REFERENCES

10

(6) glycemic targets. [LINK]

Diabetes Care, 2015

12

standards of medical care for type 2 diabetes in china 2019. [LINK]

Diabetes/Metabolism Research and Reviews, 2019